

- Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. *J Natl Cancer Inst* 1981;66:1191–308.
- Willett WC. Diet, nutrition, and avoidable cancer. *Environ Health Perspect* 1995;103:165–170.
- Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. *Cancer Detect Prev* 2008;32:190–199.
- Warren S. The immediate cause of death in cancer. *Am J Med Sci* 1932;185:610–615.
- Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer patients. *Cancer* 1974;33:568–573.
- DeWys WD. Anorexia as a general effect of cancer. *Cancer* 1979;43:2013–2019.
- Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med* 1980;69:491–497.
- Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. *Curr Opin Clin Nutr Metab Care* 2008;11:400–407.
- McClement S. Cancer anorexia-cachexia syndrome: psychological effect on the patient and family. *J Wound Ostomy Continence Nurs* 2005;32:264–268.
- Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. *Semin Oncol* 1995;22:98–111.
- Puccio M, Nathanson L. The cancer cachexia syndrome. *Semin Oncol* 1997;24:277–287.
- Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Cancer: disease and nutrition are key determinants of patients' quality of life. *Support Care Cancer* 2004;12:246–252.
- Lis CG, Gupta D, Lammersfeld CA, et al. Role of nutritional status in predicting quality of life outcomes in cancer—a systematic review of the epidemiological literature. *Nutr J* 2012;11:27.
- August D, Huhmann M. Nutritional care of cancer patients. In: Norton JA, Barie P, Bollinger RR, et al., eds. *Surgery: Basic Science and Clinical Evidence*. 2nd ed. New York: Springer Publishing; 2008: 2123–2149.
- Studley H. Percentage of weight loss. *JAMA* 1936;106:458–460.
- Mullen JT, Davenport DL, Hutter MM, et al. Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. *Ann Surg Oncol* 2008;15:2164–2172.
- Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625–1638.
- August DA, Huhmann MB. Nutritional support of the cancer patient. In: Ross CA, Caballero B, Cousins RJ, et al., eds. *Modern Nutrition in Health and Disease*. Philadelphia, PA: Lippincott, Williams and Wilkins; 2013: 1194–1213.
- Fletcher AL, Marks DL. Central mechanisms controlling appetite and food intake in a cancer setting: an update. *Curr Opin Support Palliat Care* 2007;1:306–311.
- Tisdale MJ. Cancer cachexia. *Curr Opin Gastroenterol* 2010;26:146–151.
- Skipworth RJ, Fearon KC. The scientific rationale for optimizing nutritional support in cancer. *Eur J Gastroenterol Hepatol* 2007;19:371–377.
- Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. *Nutrition* 1997;13:1–7.
- Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. *Cancer* 1989;63:330–334.
- Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. *Lancet Oncol* 2003;4:686–694.
- Roscoe JA, Bushunov P, Morrow GR, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. *Cancer* 2004;101:2701–2708.
- Kern KA, Norton JA. Cancer cachexia. *JPEN J Parenter Enteral Nutr* 1988;12: 286–298.
- Hyltander A, Drott C, Korner U, et al. Elevated energy expenditure in cancer patients with solid tumours. *Eur J Cancer* 1991;27:9–15.
- Arbeit JM, Lees DE, Corsey R, et al. Resting energy expenditure in controls and cancer patients with localized and diffuse disease. *Ann Surg* 1984; 199:292–298.
- Barak N, Wall-Alonso E, Sitrin MD. Evaluation of stress factors and body weight adjustments currently used to estimate energy expenditure in hospitalized patients. *JPEN J Parenter Enteral Nutr* 2002;26:231–238.
- MacDonald A, Hildebrandt L. Comparison of formulaic equations to determine energy expenditure in the critically ill patient. *Nutrition* 2003;19: 233–239.
- Reeves MM, Battistutta D, Capra S, et al. Resting energy expenditure in patients with solid tumors undergoing anticancer therapy. *Nutrition* 2006;22: 609–615.
- Johnson C, Salle A, Lorimier G, et al. Cancer cachexia: measured and predicted resting energy expenditures for nutritional needs evaluation. *Nutrition* 2008;24:443–450.
- Bosy-Westphal A, Reinecke U, Schlorke T, et al. Effect of organ and tissue masses on resting energy expenditure in underweight, normal weight and obese adults. *Int J Obes Relat Metab Disord* 2004;28:72–79.
- Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. *Ann Surg* 1994;219:325–331.
- Ravasco P, Monteiro-Grillo I, Camilo M. Colorectal cancer: intrinsic characteristics modulate cancer energy expenditure and the risk of cachexia. *Cancer Invest* 2007;25:308–314.
- Cao DX, Wu GH, Zhang B, et al. Resting energy expenditure and body composition in patients with newly detected cancer. *Clin Nutr* 2010;29:72–77.
- Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. *Ann Surg* 1983;197:152–162.
- Hansell DT, Davies JW, Burns HJ. The relationship between resting energy expenditure and weight loss in benign and malignant disease. *Ann Surg* 1986;203:240–245.
- Vaisman N, Lusthaus M, Niv E, et al. Effect of tumor load on energy expenditure in patients with pancreatic cancer. *Pancreas* 2012;41:230–232.
- Fearon KC, Hansell DT, Preston T, et al. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. *Cancer Res* 1988;48:2590–2595.
- Jebb SA, Osborne RJ, Dixon AK, et al. Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. *Ann Oncol* 1994;5:915–919.
- Dempsey DT, Feurer ID, Knox LS, et al. Energy expenditure in malnourished gastrointestinal cancer patients. *Cancer* 1984;53:1265–1273.
- Tisdale MJ. Tumor-host interactions. *J Cell Biochem* 2004;93:871–877.
- Lundholm K, Edstrom S, Karlberg I, et al. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. *Cancer* 1982;50:1142–1150.
- Jeevanandam M, Legaspi A, Lowry SF, et al. Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease. *JPEN J Parenter Enteral Nutr* 1988;12:229–236.
- Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. *Ann Surg* 1987;205:368–376.
- Warburg O. On the origin of cancer cells. *Science* 1956;123:309–314.
- Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia—pathophysiology and management. *J Gastroenterol* 2013;48:574–594.
- Garcia-Martinez C, Costelli P, Lopez-Soriano FJ, et al. Is TNF really involved in cachexia? *Cancer Invest* 1997;15:47–54.
- Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. *J Cachexia Sarcopenia Muscle* 2010;1:9–21.
- Darling G, Fraker DL, Jensen JC, et al. Cachectic effects of recombinant human tumor necrosis factor in rats. *Cancer Res* 1990;50:4008–4013.
- Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. *Cell* 1987;50:555–563.
- Toomey D, Redmond HP, Bouchier-Hayes D. Mechanisms mediating cancer cachexia. *Cancer* 1995;76:2418–2426.
- Fischer E, Marano MA, Barber AE, et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. *Am J Physiol* 1991;261:R442–R452.
- Diakowska D, Krzystek-Korpaczka M, Markocka-Maczka K, et al. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. *Cytokine* 2010;51:132–137.
- Smiechowska J, Utech A, Taffet G, et al. Adipokines in patients with cancer anorexia and cachexia. *J Invest Med* 2010;58:554–559.
- Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. *Endocrinology* 2010;151:3773–3782.
- Schreiber R, Selbach K, Asmussen M, et al. Effects of serotonin(1/2) receptor agonists on dark-phase food and water intake in rats. *Pharmacol Biochem Behav* 2000;67:291–305.
- Dannhauser A, Van Zyl JM, Nel CJ. Preoperative nutritional status and prognostic nutritional index in patients with benign disease undergoing abdominal operations—Part II. *J Am Coll Nutr* 1995;14:91–98.
- Dannhauser A, Van Zyl JM, Nel CJ. Preoperative nutritional status and prognostic nutritional index in patients with benign disease undergoing abdominal operations—Part I. *J Am Coll Nutr* 1995;14:80–90.
- Bunston T, Mackie A, Jones D, et al. Identifying the nonmedical concerns of patients with ocular melanoma. *J Ophthalmic Nurs Technol* 1994;13: 227–237.
- Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. *Eur J Clin Nutr* 2002;56:779–785.
- Andrew IM, Waterfield K, Hildreth AJ, et al. Quantifying the impact of standardized assessment and symptom management tools on symptoms associated with cancer-induced anorexia cachexia syndrome. *Palliat Med* 2009;23:680–688.
- Reid J, McKenna H, Fitzsimons D, et al. The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members. *Int J Nurs Stud* 2009;46:606–616.
- Porter S, Millar C, Reid J. Cancer cachexia care: the contribution of qualitative research to evidence-based practice. *Cancer Nurs* 2012;35:E30–E38.

66. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. *Nutrition* 2001;17:S1–S20.
67. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. *J Clin Oncol* 1993;11:762–767.
68. De Conno F, Martini C, Zecca E, et al. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. *Eur J Cancer* 1998;34:1705–1709.
69. Skarlos DV, Fountzilias G, Pavlidis N, et al. Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. *Acta Oncol* 1993;32:37–41.
70. Yeh S, Wu SY, Levine DM, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. *J Nutr Health Aging* 2000;4:246–251.
71. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. *Nutrition* 2008;24:305–313.
72. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* 2002;20:567–573.
73. Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. *Semin Oncol* 1998;25:35–44.
74. Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. *Surgery* 1995;117:260–267.
75. Wolf RF, Ng B, Weksler B, et al. Effect of growth hormone on tumor and host in an animal model. *Ann Surg Oncol* 1994;1:314–320.
76. Ng EH, Rock CS, Lazarus DD, et al. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. *Am J Physiol* 1992;262:R426–R431.
77. Tomas FM, Chandler CS, Coyle P, et al. Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats. *Biochem J* 1994;301:769–775.
78. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. *J Clin Endocrinol Metab* 2001;86:5992.
79. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. *Nutrition* 2008;24:806–814.
80. Lissoni P. Is there a role for melatonin in supportive care? *Support Care Cancer* 2002;10:110–116.
81. Fanelli M, Sarmiento R, Cattuso D, et al. Thalidomide: a new anticancer drug? *Expert Opin Investig Drugs* 2003;12:1211–1225.
82. Goldberg RM, Loprinzi CL, Maillard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 1995;13:2856–2859.
83. Tisdale MJ. Cachexia in cancer patients. *Nat Rev Cancer* 2002;2:862–871.
84. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. *J Clin Oncol* 2006;24:3401–3407.
85. Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life. *J Pain Symptom Manage* 2009;37:1069–1077.
86. Licitra L, Spinazze S, Roila F. Antiemetic therapy. *Crit Rev Oncol Hematol* 2002;43:93–101.
87. Huhmann MB. *The Impact of Medical Nutrition Therapy by a Registered Dietitian on Clinical and Patient Oriented Outcomes in Cancer Patients*. Newark, NJ: University of Medicine and Dentistry of New Jersey; 2008.
88. Levy MH, Back A, Benedetti C, et al. NCCN clinical practice guidelines in oncology: palliative care. *J Natl Compr Canc Netw* 2009;7:436–473.
89. Radbruch L, Elsnér F, Trottenberg P, et al. *Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients*. European Clinical Guidelines. Aachen, Germany: Department of Palliative Medicine/European Palliative Care Research Collaborative; 2010.
90. Fisch M. Treatment of depression in cancer. *J Natl Cancer Inst Monogr* 2004;105–111.
91. Valente SM, Saunders JM, Cohen MZ. Evaluating depression among patients with cancer. *Cancer Pract* 1994;2:65–71.
92. Homsy J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. *Am J Hosp Palliat Care* 2001;18:403–407.
93. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. *J Pain Symptom Manage* 2002;23:442–447.
94. August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. *JPEN J Parenter Enteral Nutr* 2009;33:472–500.
95. Bozzetti F, Arends J, Lundholm K, et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. *Clin Nutr* 2009;28:445–454.
96. Huhmann MB, August DA. Review of American Society for Parenteral and Enteral Nutrition (ASPEN) Clinical Guidelines for Nutrition Support in Cancer Patients: nutrition screening and assessment. *Nutr Clin Pract* 2008;23:182–188.
97. Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. *Br J Cancer* 2004;91:447–452.
98. Isenring E, Capra S, Bauer J. Patient satisfaction is rated higher by radiation oncology outpatients receiving nutrition intervention compared with usual care. *J Hum Nutr Diet* 2004;17:145–152.
99. Piquet MA, Ozsahin M, Larpin I, et al. Early nutritional intervention in oropharyngeal cancer patients undergoing radiotherapy. *Support Care Cancer* 2002;10:502–504.
100. Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncol* 2005;23:1431–1438.
101. Braga M, Gianotti L, Gentilini O, et al. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. *Crit Care Med* 2001;29:242–248.
102. Papapietro K, Diaz E, Csendes A, et al. [Early enteral nutrition in cancer patients subjected to a total gastrectomy]. *Rev Med Chil* 2002;130:1125–1130.
103. Jiang XH, Li N, Li JS. Intestinal permeability in patients after surgical trauma and effect of enteral nutrition versus parenteral nutrition. *World J Gastroenterol* 2003;9:1878–1870.
104. Bozzetti F. Rationale and indications for preoperative feeding of malnourished surgical cancer patients. *Nutrition* 2002;18:953–959.
105. Shike M, Russel DM, Detsky AS, et al. Changes in body composition in patients with small-cell lung cancer. The effect of total parenteral nutrition as an adjunct to chemotherapy. *Ann Intern Med* 1984;101:303–309.
106. Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. *N Engl J Med* 1991;325:525–532.
107. Greco M, Capretti G, Beretta L, et al. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. *World J Surg* 2014;38:1531–1541.
108. Casar MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. *N Engl J Med* 2011;365:506–517.
109. Itkin M, DeLegge MH, Fang JC, et al. Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, with endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). *Gastroenterology* 2011;141:742–765.
110. Laviano A, Rossi-Fanelli F. Pathogenesis of cancer anorexia: still doubts after all these years? *Nutrition* 2003;19:67–68.
111. Marano L, Porfidia R, Pezzella M, et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancer patients: a prospective randomized study. *Ann Surg Oncol* 2013;20:3912–3918.
112. Marik PE, Zaloga GP. Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature. *JPEN J Parenter Enteral Nutr* 2010;34:378–386.
113. Waitzberg DL, Saito H, Plank LD, et al. Postsurgical infections are reduced with specialized nutrition support. *World J Surg* 2006;30:1592–1604.
114. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. *Crit Care Med* 1999;27:2799–2805.
115. Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. *JAMA* 2001;286:944–953.
116. Heys SD, Walker LC, Smith I, et al. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. *Ann Surg* 1999;229:467–477.
117. Bozzetti F, Mori V. Nutritional support and tumour growth in humans: a narrative review of the literature. *Clin Nutr* 2009;28:226–230.
118. Popp MB, Wagner SC, Brito OJ. Host and tumor responses to increasing levels of intravenous nutritional support. *Surgery* 1983;94:300–308.
119. Daly JL, Thorn A. Neoplastic diseases. In: Kinney J, Jeejeebhoy KN, Hill C, Owen O, eds. *Nutrition and Metabolism in Patient Care*. Philadelphia: Saunders; 1988: 567–587.
120. Torosian MH. Stimulation of tumor growth by nutrition support. *JPEN J Parenter Enteral Nutr* 1992;16:728–755.
121. Baron PL, Lawrence W Jr, Chan WM, et al. Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer. *Arch Surg* 1986;121:1282–1286.
122. Frank JL, Lawrence W Jr, Banks WL Jr, et al. Modulation of cell cycle kinetics in human cancer with total parenteral nutrition. *Cancer* 1992;69:1858–1864.
123. Heys SD, Park KC, McNurlan MA, et al. Stimulation of protein synthesis in human tumours by parenteral nutrition: evidence for modulation of tumour growth. *Br J Surg* 1991;78:483–487.
124. Pacelli F, Bossola M, Teodori L, et al. Parenteral nutrition does not stimulate tumor proliferation in malnourished gastric cancer patients. *JPEN J Parenter Enteral Nutr* 2007;31:451–455.
125. Kavanagh BP, McCowen KC. Clinical practice. Glycemic control in the ICU. *N Engl J Med* 2010;363:2540–2546.
126. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283–1297.
127. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359–1367.
128. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006;354:449–461.

129. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med* 2009;35:1738–1748.
130. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and post-arterial resuscitation in severe sepsis. *N Engl J Med* 2008;358:125–139.
131. Inzucchi SE, Siegel MD. Glucose control in the ICU—how tight is too tight? *N Engl J Med* 2009;360:1346–1349.
132. Huhmann MB, August DA. Perioperative nutrition support in cancer patients. *Nutr Clin Pract* 2012;27:586–592.
133. Maerz LL, Akhtar S. Perioperative glycemic management in 2011: paradigm shifts. *Curr Opin Crit Care* 2011;17:370–375.
134. Reeds D. Near-normal glycemia for critically ill patients receiving nutrition support: fact or folly. *Curr Opin Gastroenterol* 2010;26:152–155.
135. Howard L. Home parenteral nutrition in patients with a cancer diagnosis. *JPEN J Parenter Enteral Nutr* 1992;16:93S–99S.
136. Orrevall Y, Tishelman C, Permert J, et al. The use of artificial nutrition among cancer patients enrolled in palliative home care services. *Palliat Med* 2009;23:556–564.
137. Bachmann P, Marti-Massoud C, Blanc-Vincent MP, et al. Summary version of the Standards, Options and Recommendations for palliative or terminal nutrition in adults with progressive cancer (2001). *Br J Cancer* 2003;89: S107–S110.
138. Mackenzie ML, Gramlich L. Home parenteral nutrition in advanced cancer: where are we? *Appl Physiol Nutr Metab* 2008;33:1–11.
139. Rolandelli RH, Gupta D, Wilmore D. Nutritional support. In: Souba WW, Fink MP, Jurkovich GJ, et al., eds. *ACS Surgery Principles and Practice*. New York: WebMD Professional Publishing; 2007: 1789–1809.